Table 1.
Characteristics of the studies included in this meta-analysis
| Gender (Male/Female) | Mean age (Y) | Treatment design | Follow-up (M) | Study design | Stages | Outcomes assessed | ||
|---|---|---|---|---|---|---|---|---|
| Exp | Con | |||||||
| Jiang/200 6[11] |
Exp: 21/11; Con: 18/7 |
Exp: 54; Con: 52 |
CIK + FOLFOX4 (N = 32) | FOLFOX4 (N = 25) | 60 | Prospective | GC: IV | CR, PR, ORR, QOL |
| Shi/201 2[12] |
Exp: 43/31; Con: 58/19 |
Exp: 58 ± 2.1; Con: 56 ± 1.5 |
CIK + COD (N = 74) | COD (N = 77) | 80 | Retrospective | GC: III, IV | OS, PFS |
| Zhao/201 3[13] |
Exp: 40/13; Con: 87/25 |
NA | CIK + FUP or FOLFOX4 (N = 53) | FUP or FOLFOX4 (N = 112) | 120 | Retrospective | GC: II, III | OS, PFS |
| Lin/201 5[14] |
Exp: 76/58; Con: 64/57 |
NA | DC–CIK + 5-FU, FOLFOX/XELOX (N = 134) | 5-FU, FOLFOX/XELOX (N = 121) | 50 | Prospective | CRC: KPS score > 60 | Thrombocytopenia, nausea, vomiting, abnormal liver function |
| Mu/201 6[15] |
Exp: 10/3; Con: 10/5 |
NA | CIK + FOLFOX4/DCF (N = 13) | FOLFOX4/DCF (N = 15) | 24 | Prospective | GC: III, IV | OS, PFS, CR, PR, ORR, thrombocytopenia, nausea, vomiting, neutropenia |
| Zhao/201 6[16] |
Exp: 41/20; Con: 41/20 |
Exp: 58; Con: 60 |
CIK + FOLFOX4 (N = 61) | FOLFOX4 (N = 61) | 72 | Prospective | CRC: KPS score > 70 | OS, PFS, CR, PR, ORR, neutropenia |
| Peng/201 7[17] |
Exp: 14/9; Con: 15/8 |
Exp: 52.2 ± 7.9; Con: 51.4 ± 8.5 |
CIK + FOLFOX4(N = 23) | FOLFOX4 (N = 23) | 50 | Prospective | CRC: II, III | QOL, nausea, vomiting, abnormal liver function, myelosuppression |
| Wang/201 7[18] |
Exp: 38/13; Con: 73/23 |
NA | CIK + FP (N = 51) | FP (N = 96) | 80 | Prospective | GC: II, III | OS, PFS, myelosuppression |
| Xie/201 7[19] |
Exp: 39/32; Con: 40/31 |
Exp: 55.3 ± 14.6; Con: 55.6 ± 14.3 |
DC-CIK + FOLFIRI (N = 71) | FOLFIRI (N = 71) | 120 | Retrospective | CRC: III, IV | OS, PFS, QOL |
CIK Cytokine-induced killer biotherapy, COD cisplatin, oxaliplatin, and docetaxel, Con control group, CR complete response, DC dendritic cell, DCF docetaxel, cisplatin, 5-florouracil, Exp experimental group, FOLFIRI irinotecan (CPT-11), leucovorin (LV), and 5-FU regimen, FOLFOX4 5-fluorouridine, leucovorin, and oxaliplatin, FP 5-fluorouracil- and platinum, KPS Karnofsky performance status, M months, NA Not available, ORR overall response rate, OS overall survival, PFS progression-free survival, PR partial response, QOL quality of life, Y years